1National Institutes of Health National Heart,Lung, and Blood Institute. NHLBI/WHO workshop report: global strategy for asthma management and prevention. Issued, 1995.1 - 113.
2National Institutes of Health National Heart, Lung ,and Blood Institute. NHLBI/WHO workshop report: global strategy for asthma management and prevention. Revised, 2002.1 - 176.
1Martinez FD,Wright AL,Taussig LM, et al. Asthma and wheezing in the first six years of life. N Engl J Med, 1995,332(3) : 133.
2Politiek MJ, Boorsma M, Aalbers R. Comparison of formoterol,salbutamol and salmeterol in methacholine-induced severe bronchoconstriction. Ettr Respir J, 1999,13 (5) :988.
3Goodman LS, Gilman A. The pharmacological basis of therapeutics.9th ed. New York,NY: Mc Gram-Hill Book Co, 1996.1459.
4Global Initiative For Asthma. National institutes of health. National Heart, Lung, and Blood Institute, Revised,2002.105.
5团体著者，中华结核和呼吸杂志，1993年，16卷，哮喘增刊，5页
6团体著者，中华结核和呼吸杂志，1993年，16卷，哮喘增刊，6页
7Morali T, Yilmaz A, Erkan F, et al. Efficacy of inhaled budesonide and oral theophylline in asthmatic subjects. J Asthma, 2001,38:673-679.
9Sher ER, Leung DY, Surs W, et al. Steroid-resistant asthma.Cellular mechanisms contributing to inadequate response to glucocorticoid therapy. Clin Invest, 1994, 93: 33-39.
10Umland SP, Schleimer RP, Johnston SL. Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. Pulm Pharmacol Ther, 2002, 15:35-50.
